"Organon discontinues endometriosis drug after Phase II flunk" was originally created and published by Clinical Trials Arena, ...

Healthcare company Organon & Co. (OGN) said on Wednesday that it is discontinuing the development of its investigational ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

The Global Endometriosis Treatment Market is expected to reach at a CAGR of 10.62% during the forecast period 2025-2033. Sai Kiran DataM Intelligence 4Market Research +1 877-441-4866 ... Visit us on ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Endometriosis impacts daily functioning because of the intense cramps. Know how yoga may help support the pain.

A new study from Karolinska Institutet involving over a million women links difficult childhood experiences to the risk of ...

A study found that a low FODMAP diet significantly reduced gastrointestinal symptoms such as abdominal pain and bloating in ...

New research links endometriosis to autoimmune diseases, revealing shared mechanisms that may lead to earlier diagnosis and ...

Women and girls are playing thousands for endometriosis treatments unavailable in regional Queensland. One family from Mackay ...